DE60125062D1 - Quetiapin zur Behandlung der Dyskinesie in nicht-psychotischen Patienten - Google Patents

Quetiapin zur Behandlung der Dyskinesie in nicht-psychotischen Patienten

Info

Publication number
DE60125062D1
DE60125062D1 DE60125062T DE60125062T DE60125062D1 DE 60125062 D1 DE60125062 D1 DE 60125062D1 DE 60125062 T DE60125062 T DE 60125062T DE 60125062 T DE60125062 T DE 60125062T DE 60125062 D1 DE60125062 D1 DE 60125062D1
Authority
DE
Germany
Prior art keywords
quetiapine
treatment
dopaminergic
dyskinesia
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60125062T
Other languages
English (en)
Other versions
DE60125062T2 (de
Inventor
Jeffrey Goldstein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of DE60125062D1 publication Critical patent/DE60125062D1/de
Application granted granted Critical
Publication of DE60125062T2 publication Critical patent/DE60125062T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
DE60125062T 2000-12-20 2001-12-18 Quetiapin zur Behandlung der Dyskinesie in nicht-psychotischen Patienten Expired - Fee Related DE60125062T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28758200P 2000-12-20 2000-12-20
US287582P 2000-12-20
PCT/SE2001/002820 WO2002049652A1 (en) 2000-12-20 2001-12-18 Method of treatment

Publications (2)

Publication Number Publication Date
DE60125062D1 true DE60125062D1 (de) 2007-01-18
DE60125062T2 DE60125062T2 (de) 2007-05-31

Family

ID=23103533

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60125062T Expired - Fee Related DE60125062T2 (de) 2000-12-20 2001-12-18 Quetiapin zur Behandlung der Dyskinesie in nicht-psychotischen Patienten

Country Status (9)

Country Link
US (1) US20040058909A1 (de)
EP (1) EP1345610B1 (de)
JP (1) JP2004516271A (de)
AT (1) ATE347364T1 (de)
AU (1) AU2002216557A1 (de)
DE (1) DE60125062T2 (de)
ES (1) ES2275619T3 (de)
HK (1) HK1057170A1 (de)
WO (1) WO2002049652A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI292316B (en) * 1999-10-11 2008-01-11 Sod Conseils Rech Applic Pharmaceutical composition of thiazole derivatives intended to inhibit mao and/or lipidic peroxidation and/or to act as modulators of sodium channels and the use thereof
FR2888116A1 (fr) * 2005-07-08 2007-01-12 Sod Conseils Rech Applic Derives de thiazoles pour traiter les dyskinesies
WO2008118141A2 (en) * 2006-10-17 2008-10-02 Acadia Pharmaceuticals Inc. Use of cannabinoid modulating compounds in combination with other therapeutic compounds for adjunctive therapy
CA2704279C (en) * 2006-11-03 2014-09-30 University Of Saskatchewan Method of treating demyelination diseases
ITMI20100260A1 (it) * 2010-02-19 2011-08-20 Giulio Scigliano Composizione farmaceutica contenente un farmaco per ridurre gli effetti collaterali dei farmaci antipsicotici
WO2018191450A2 (en) 2017-04-14 2018-10-18 National Taiwan University Hospital Gene therapy for aadc deficiency
US9993486B1 (en) 2017-06-19 2018-06-12 Tlc Therapeutics, Llc Oral quetiapine suspension formulations with extended shelf life and enhanced bioavailability

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607684D0 (en) * 1986-03-27 1986-04-30 Ici America Inc Thiazepine compounds

Also Published As

Publication number Publication date
WO2002049652A1 (en) 2002-06-27
JP2004516271A (ja) 2004-06-03
ATE347364T1 (de) 2006-12-15
AU2002216557A1 (en) 2002-07-01
US20040058909A1 (en) 2004-03-25
HK1057170A1 (en) 2004-03-19
EP1345610A1 (de) 2003-09-24
EP1345610B1 (de) 2006-12-06
DE60125062T2 (de) 2007-05-31
ES2275619T3 (es) 2007-06-16

Similar Documents

Publication Publication Date Title
YU77000A (sh) Primena peg-ifn-alfa i ribavirina za lečenje hroničnog hepatitisa c
NO20014842D0 (no) Docetaksel i kombinasjon med rhuMAb HER2 for behandling av kreft
EA200101089A1 (ru) Новый способ лечения
EA200001044A3 (ru) Соединения для лечения женской сексуальной дисфункции
DK1373215T3 (da) Gelanamycinderivater egnet til behandling af cancer
HUP0101645A2 (hu) Riluzol és L-DOPA kombinációi a Parkinson kór kezelésére
WO2002056745A3 (en) Method of treating parkinson's disease
ATE347364T1 (de) Quetiapin zur behandlung der dyskinesie in nicht- psychotischen patienten
DK1689404T3 (da) Kombination af et-743 med 5-fluoracil-prodrugs til behandling af cancer
BR0201974A (pt) Composição farmacêutica para tratamento de alterações do sono
BR0211855A (pt) Medicamento e método para tratamento e melhoria da qualidade restauradora do sono
BR0009380A (pt) Tratamento de câncer melhorado comtemozolomida
PT1237562E (pt) Processo de preparacao de extractos de micania contendo micanolida e di-hidromicanolida e utilizacao no tratamento das doencas proliferativas
BR0307022A (pt) Método de tratamento de um paciente que precisa de analgesia
DK1077683T3 (da) Antidepressiv behandling
RU2002103808A (ru) Способ лечения болевого синдрома у онкологических больных
DK1244438T3 (da) Anvendelse af beta-adrenoceptorantagonister til fremstilling af et medikament til behandling af sygdomme i den ydre nethinde
ATE431147T1 (de) Mittel zur behandlung des integrationsdysfunktionssyndroms
IL159770A0 (en) Calcium salts with cytotoxic activity
BR0311180A (pt) Métodos para o tratamento de doenças e condições respiratórias utilizando um inibidor seletivo da inos
RU2002105074A (ru) Способ лечения и профилактики развития гипертрофических и келоидных рубцов
FI20010233A0 (fi) Menetelmä sydämen vajaatoiminnan hoitoon
HK1042238A1 (en) Treatment of symptoms of parkinson's disease with an agent comprising a dopaminergic substance and a local anaesthetic of the anilide group
DE60037402D1 (de) Behandlung von autoimmunkrankheiten mit einem extrakt von amerikanischem ginseng
BR0309139A (pt) Processo de tratamento

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee